Biohaven Ltd. (NYSE:BHVN – Get Free Report) traded down 8.9% on Wednesday . The company traded as low as $13.53 and last traded at $13.5340. 1,222,212 shares changed hands during trading, a decline of 55% from the average session volume of 2,716,987 shares. The stock had previously closed at $14.85.
Analyst Upgrades and Downgrades
BHVN has been the topic of a number of recent research reports. Needham & Company LLC set a $11.00 price target on Biohaven in a research report on Monday, June 29th. Morgan Stanley upped their price objective on shares of Biohaven from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Canaccord Genuity Group set a $21.00 target price on shares of Biohaven in a report on Friday, August 28th. Royal Bank Of Canada downgraded shares of Biohaven from an “outperform” rating to a “sector perform” rating and cut their target price for the company from $23.00 to $19.00 in a research report on Tuesday, September 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Biohaven in a report on Friday, August 28th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Biohaven presently has an average rating of “Moderate Buy” and an average target price of $18.69.
Get Our Latest Analysis on BHVN
Biohaven Stock Performance
Biohaven (NYSE:BHVN – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.15). Analysts anticipate that Biohaven Ltd. will post -3.33 EPS for the current year.
Hedge Funds Weigh In On Biohaven
Several hedge funds have recently made changes to their positions in BHVN. Opaleye Management Inc. acquired a new stake in shares of Biohaven during the second quarter worth about $1,159,000. BlueCrest Capital Management Ltd purchased a new stake in shares of Biohaven during the 2nd quarter worth about $60,000. Engineers Gate Manager LP acquired a new stake in shares of Biohaven during the 2nd quarter valued at about $581,000. Integrated Wealth Concepts LLC increased its stake in shares of Biohaven by 10.4% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 12,653 shares of the company’s stock valued at $188,000 after purchasing an additional 1,189 shares in the last quarter. Finally, NewEdge Advisors LLC raised its holdings in Biohaven by 1,525.3% in the 2nd quarter. NewEdge Advisors LLC now owns 16,659 shares of the company’s stock worth $248,000 after purchasing an additional 15,634 shares during the period. 88.78% of the stock is owned by institutional investors and hedge funds.
About Biohaven
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and immunological disorders. The company’s research programs use a range of approaches, including small-molecule medicines, biologics and other targeted therapies, with the goal of addressing diseases that have limited or inadequate treatment options.
Biohaven’s pipeline has included investigational treatments for conditions such as epilepsy, obsessive-compulsive disorder, neurodegenerative diseases, neuroinflammatory disorders and immune-mediated diseases.
Featured Articles
- Five stocks we like better than Biohaven
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.
